Toll-like receptor 9 (TLR9) and Toll-like receptor 2 (TLR2) (TLR9/TLR2)

Thymosin alpha 1 (Tα1) is a synthetic 28-amino acid peptide that acts as a potent immunomodulator by targeting specific innate and adaptive immune receptors, primarily Toll-like receptor 9 (TLR9) and Toll-like receptor 2 (TLR2) (Garaci et al., 2015). These receptors are predominantly expressed on myeloid and plasmacytoid dendritic cells, where Tα1 binding initiates the MyD88-dependent signaling cascade (Serafino et al., 2014). This activation leads to the nuclear translocation of NF-κB and IRF7, resulting in the secretion of type I interferons and pro-inflammatory cytokines such as IL-12, which promote a Th1-biased immune response (King & Tuthill, 2016). Tα1 also enhances the maturation of T-cells and increases the expression of MHC class I molecules, improving the host's ability to recognize and eliminate virally infected or malignant cells (UniProt Q9NR96). Clinically, the drug thymalfasin (Zadaxin) utilizes these pathways to treat chronic hepatitis B and C, as well as serving as an adjuvant in cancer immunotherapy and vaccine responses (DrugBank DB00038). The therapeutic value of targeting these receptors lies in the ability to restore immune homeostasis and boost effector cell functions in immunocompromised states.

Other names

Thymosin alpha 1 receptorsTα1-responsive receptorsTLR9TLR2Prothymosin alpha-derived peptide receptors

Agonism of TLR9 and TLR2 on dendritic cells, triggering the MyD88-dependent signaling pathway to activate NF-κB and IRF7, leading to type I interferon production and Th1 immune polarization.